Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

NCT04085991 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Drug no longer available

Conditions

Prostate Cancer
Prostate Adenocarcinoma
Prostatic Neoplasms
Metastatic Prostate Cancer
Metastatic Prostatic Adenocarcinoma
Metastatic Prostate Carcinoma in the Soft Tissue

Interventions

DRUG: 131I-PSMA-1095 Radioligand Therapy (RLT)

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital